John Erbey is the CEO and founder of Roivios, a medical technology company advancing solutions to sustain kidney function during acute clinical stress. He holds a Doctor of Philosophy from the University of Pittsburgh, is a Delta Omega member, and has more than 25 years of leadership in medical device development and health care innovation.
His work focuses on the clinical and economic impact of timing in kidney preservation during high-risk surgical moments. Roivios is currently advancing this research through the BIPASS Study and the GRADIENT Trial, with additional work outlined on the company's studies page.
He shares updates on LinkedIn and through the Roivios company page.
The conversation in the surgical ICU happens the same way every time.
“His creatinine spiked post-op, but it came back down before discharge. The labs look normal now. The kidney recovered.”
Cardiac surgeons hear this reassurance so often it’s become standard. The patient leaves the hospital with normal kidney function on the discharge summary. By every conventional metric, the surgery was a success. The acute kidney injury was resolved.
Except it didn’t. Not …
Read more…
When normal creatinine hides post-operative kidney injury
